Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Duke PA Onc dmethods
Duke PA Oncology diagnostic methods
| Question | Answer |
|---|---|
| The ability of a test to rule out a disease | Sensitivity |
| The percentage of people with cancer who will have an abnormal test | Sensitiviy |
| The percentage of people without cancer whose test is negative | Specificity |
| The ability of a test to rule in disease | Specificity |
| Probability that people with an abnormal test actually have cancer | Positive predictive value |
| Probability that a negative test will predict that a person does not have cancer | Negative predictive value |
| Proteins normally found in larger amounts during fetal development | Antigens |
| These are examples of which type of tumor marker; AFP, CEA, PSA, CA-125, Bence Jones Proteins | Antigens |
| These are examples of which type of tumor marker; Prostatic Acid Phosphatase, Galactosyl transferase II | Enzymes |
| This marker is often associated with tumors of endocrine glands | Hormones |
| These are examples of which type of tumor marker; Beta-HCG, Human Calcitonin | Hormones |
| Genes that are useful in fetal development but when activate in mature cells trigger tumor growth | Oncogenes |
| These are examples of which type of tumor marker; BRCA 1, BRCA 2, Philadelphia chromosome | Oncogenes |
| Philadelphia Chromosome is associated with which type of cancer | Chronic Myelogenous Leukemia-CML |
| Cell surface proteins that affect the rate of tumor development by binding to hormones and growth factors | Tissue receptors |
| These are examples of which type of tumor marker; ER assay, PR assay, EGFR | Tissue receptors |
| What goes down as prevalence of disease goes down | Positive predictive value |
| Increased in 80-90% of patients with hepatocellular carcinoma | Alpha-Fetoprotein (AFP) |
| Patients with cirrhosis and active hepatitis should be screened with which tumor marker every 3-4 months | Alpha-Fetoprotein (AFP) |
| Used primarily to detect and monitor clinical course of Multiple Myeloma. It is not found in the blood b/c it is effeciently filtered by the kidneys. Considered to be the first tumor marker. | Bence Jones Proteins |
| This hormone tumor marker is normally negative except in pregnancy, and is never found in cancer free males. | Beta-HCG |
| This hormone tumor marker is primarily associated with the following; Hydatidiform mole of the uterus, chriocarcinoma of the uterus, and germ cell tumors of the ovaries | Beta-HCG |
| High levels of this hormone are almost always pathognomonic for germ cell neoplasm in men. | Beta-HCG |
| This antigen is useful in diagnosis, evaluation of therapy, and sruveillance in patients with pancreatic and hepatobiliary cancer | CA 19-9 |
| This antigen is elevated in 80-90% of women with ovarian cancer. | CA 125 |
| This antigen is used in determining the extent of disease, prognosis, and response to therapy in patients with GI cancers. | Carcinoembryonic Antigen (CEA) |
| Baseline for this antigen is elevated in smokers. | Carcinoembryonic Antigen (CEA) |
| This antigen is used in screening for early detection of prostate cancer. | Prostate Specific Antigen (PSA) |
| When combined with a digital rectal exam 90% of clinically significant cancers can be detected. | Prostate Specific Antigen (PSA) |
| Not a tumor marker but a useful diagnostic tool for assessing risk of developing breast cancer in a woman in the general population | The Gail model |
| This tool takes into acount these factors when assessing 5 year and lifetime risk of developing breast cancer; current age, age at menarche, previous breast biopsies, age at first live birth, family history of breast cancer. | The Gail model |
| Breast cancer oncogenes | BRCA 1, BRCA 2 |
| Men with this mutation carry a markedly increased risk of developing prostate cancer and or colorectal cancer, and may pass the mutation to their daughters. | BRCA 2 |
| This tissue receptor indicates sensitivity to hormonal therapy. | Estrogen Receptor (ER) assay, and Progesterone Receptor (PR) Assay |
| Tumors positive for this tissue receptor are more than twice as likely to respond to hormone therapy. | ER assay |
| This tissue receptor is more often positive in postmenopausal breast cancer patients | PR assay |
| An increased level of this antigen is associated with more aggressive breast cancers. | HER 2 (neu) |
| Triple negative tumors have no hormonal target for therapy and are negative for which markers. | ER, PR, HER 2 |
| This antigen is elevated in 70-80% of patients with metastatic disease, and is rarely elevated in early stage disease. | CA 15-3 |
| This antigen is useful in monitoring response to therapy in metastatic breast cancer patients. | CA 27.29 |
| This rare marker is associated with liquid tumors; lymphoma, leukemia, multiple myeloma. | Beta2 microglobulin |
| This rare antigen is not a good screening tool b/c levels can be elevated in UTI, renal calculi, recent urinary surgery | Bladder tumor antigen (BTA) |
| This rare marker is a good screening tool for patients at risk for bladder cancer | Nuclear Matrix protein 22 (NMP22) |
| A sensitive marker for detection of bladder cancer across all disease stages and grades | Survivin |
| This hormone is used to evaluat patients with at risk for/suspected medullary carcinoma of the thyroid. | Human Calcitonin |
| This enzyme is associated with Neuroblastoma, carcinoid, and small cell lung cancer | Neuron Specific Enolase (NSA) |
| This enzyme is primarily used to diagnose, stage, and monitor efficacy of treatment in prostate cancer | Prostatic Acid Phosphatase (PAP) |
| This cancer has a 30% recurrence rate even decades after successful treatment | Thyroid cancer |
| This protein is the primary marker for surveillance of well-differentiated thyroid cancers in postoperative patients. | Thyroglobulin |
| Common tumor marker for ovarian cancer | CA 125 |
| k-ras, c-myc, abl, Her2/neu are all examples of what | Oncogenes |
| Genes that once mutated activates the growth pathway | Oncogenes |
| Only one copy needs to be mutated to induce tumorogensis | Oncogenes |
| Genes that normally inhibit growth | Tumor suppressor genes |
| A mutation of these causes a loss of inhibition | Tumor suppressor genes |
| Both copies need to be mutated to lose function | Tumor suppressor genes |
| Classic presentation fo this type of cancer is painless jaundice | Pancreatic cancer |
| Tumor marker for teratoma | Alpha-Fetoprotein (AFP) |
| No meat | No treat |
| Tissue | Is the issue |
| In what scenario do you not need a pathological specimen to initiate treatment | Pancreatic mass |
| A small needle is inserted into the mass and cells are removed for microscopic evaluation | Fine needle aspiration |
| Can be done guided or unguided | Fine needle aspiration |
| This type of biopsy is mainly applied to melanoma | Punch biopsy |
| What type of biopsy is not indicated for suspected melanoma | Shave biopsy |
| Once a tissue diagnosis positive for cancer is obtained what is the next step in treatment of the patient | Radiographic staging |
| Based on the theory that lymphatic spread proceeds through a consistent anatomic network of ducts and nodes based on tumor location | Sentinel lymph node biopsy |
| Looking for hot and blue nodes | Sentinel lymph node biopsy |
| It is recommended that those with this disorder start haveing colonoscopies in their teens | Familial adenomatous polyposis (FAP) |
| Should begin screening 10 years prior to the age of onset in the family member affected with what cancer. | Hereditary Nonpolyposis Colorectal Cancer (HNPCC) |
Created by:
bwyche
Popular Laboratory Science sets